Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Up-front polytherapy for ALK-positive lung cancer

A new study identifies the RAS-MAPK pathway to be an Achilles' heel of EML4-ALK fusion-positive lung cancer and suggests that up-front combination therapy directed against both pathways can achieve sustained suppression of tumor growth.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Up-front concurrent inhibition of ALK and MEK leads to sustained tumor growth suppression in EML4-ALK–positive lung cancer.

Marina Corral Spence/Nature Publishing Group

References

  1. Heist, R.S. & Engelman, J.A. Cancer Cell 21, 448.e2 (2012).

    Article  Google Scholar 

  2. Camidge, D.R., Pao, W. & Sequist, L.V. Nat. Rev. Clin. Oncol. 11, 473–481 (2014).

    CAS  Article  Google Scholar 

  3. Katayama, R. et al. Clin. Cancer Res. 21, 2227–2235 (2015).

    CAS  Article  Google Scholar 

  4. Hrustanovic, G. et al. Nat. Med. 21, 1038–1047 (2015).

    CAS  Article  Google Scholar 

  5. Hallberg, B. & Palmer, R.H. Nat. Rev. Cancer 13, 685–700 (2013).

    CAS  Article  Google Scholar 

  6. Tanizaki, J. et al. Br. J. Cancer 106, 763–767 (2012).

    CAS  Article  Google Scholar 

  7. Crystal, A.S. et al. Science 346, 1480–1486 (2014).

    CAS  Article  Google Scholar 

  8. Samatar, A.A. & Poulikakos, P. Nat. Rev. Drug Discov. 13, 928–942 (2014).

    CAS  Article  Google Scholar 

  9. Wilson, F.H. et al. Cancer Cell 27, 397–408 (2015).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Adrienne D Cox.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhou, B., Cox, A. Up-front polytherapy for ALK-positive lung cancer. Nat Med 21, 974–975 (2015). https://doi.org/10.1038/nm.3942

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.3942

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer